CBT-011 is an ADS compound that is a conjugate between an anti-angiogenic antibody and a small molecule drug via a proprietory linker that can be selectively cleaved in the vitreous humor. After intravitreal injection, the ADS will dissociate into the antibody drug and the small molecule drug. The two drugs will then act on  multiple pathogenic pathways to produce a synergistic effect on treatment efficacy such as inhibition of vessel leakage.